Description

Liztox 200UI — 99.8% Pure Botulinum Toxin Type A

Liztox 200UI is a botulinum toxin type A product from Huons Biopharma Co., Ltd., a South Korean biotech company with roots tracing back to 1965. Notably, Huons Biopharma achieved the first MFDS approval for a locally produced botulinum toxin in Korea in 2019. Since then, Liztox has gained regulatory approval in additional markets, including Thailand and Iraq.

This vial delivers double the toxin content of the standard 100-unit option. Additionally, it reaches the same 99.8% purity through Huons Biopharma’s BioPure Extraction Process. Because of its higher unit count, practitioners often choose it for larger treatment areas or sessions covering multiple zones.

At a Glance

Units per Vial	200 units
Purity	99.8%
Onset	3–7 days
Duration	2–8 months, depending on treatment area
Manufacturer	Huons Biopharma, South Korea

Main Benefits

• Covers larger areas per vial: 200 units reduces the need for multiple vials in bigger sessions
• Very high purity: 99.8% purity via the BioPure Extraction Process
• Clinically validated: randomized trials have shown non-inferiority to Botox in treating upper-limb spasticity
• Precise, low-diffusion profile: a 150 kDa neurotoxin structure that stays closely confined to the injection site

What’s Inside

Active Ingredient	Clostridium botulinum toxin type A (strain CBFC26) — 200 units
Stabilizer	Human serum albumin
Additive	Sodium chloride
Net Weight	Approximately 30g
Format	Lyophilized powder, single-dose vial
Manufacturer	Huons Biopharma, South Korea

Packaging and included accessories vary by supplier — check your specific listing for exact kit contents.

Mechanism of Action

Liztox blocks the release of acetylcholine at the neuromuscular junction. This induces controlled, localized muscle relaxation. As a result, both fine and deep expression lines soften. Additionally, regular treatment can help prevent new wrinkles from forming. When injected into sweat glands, meanwhile, the same mechanism reduces excessive perspiration without affecting the rest of the body.

Preparation & Dilution

Reconstitute Liztox with sterile, preservative-free 0.9% saline, adding the diluent slowly to avoid foaming.

Saline Added (200U vial)	Resulting Concentration
2.0mL	10 units per 0.1mL
4.0mL	5 units per 0.1mL
5.0mL	4 units per 0.1mL
8.0mL	2.5 units per 0.1mL

Administer within 24 hours of reconstitution, and store the diluted product refrigerated at 2–8°C in the meantime.

Treatment Areas & Indications

• Glabellar lines and lateral canthal lines (crow’s feet)
• Forehead lines, bunny lines, and chin dimpling
• Masseter area and brow-position adjustment
• Neck bands and trapezius area
• Hyperhidrosis (palms, underarms, feet)
• Blepharospasm
• Pediatric cerebral palsy-related spasticity

Dosage & Technique

For glabellar lines specifically, a standard protocol uses 20 units, administered with a 30-gauge needle. For blepharospasm, however, the initial recommended dose is 1.25 to 2.5 units (0.05 to 0.1mL) per site. Specifically, practitioners inject this into the medial and lateral pre-tarsal orbicularis oculi of the upper lid, and the lateral pre-tarsal orbicularis oculi of the lower lid.

For pediatric cerebral palsy, dosing depends on the pattern of muscle involvement. In hemiplegic patients, a total dose of 4 units per kilogram of body weight is typically used for the affected gastrocnemius muscle. In diplegic patients, practitioners divide 6 units per kilogram between both legs.

The maximum dose should not exceed 200 units per patient at any one time. As always, a qualified practitioner should determine the exact plan for each patient.

Onset & Duration

For blepharospasm, effects typically appear within 3 days and peak around 3 weeks. Similarly, for pediatric cerebral palsy applications, practitioners generally expect improvement within 4 weeks of injection. For cosmetic use, meanwhile, visible results usually appear within 3 to 7 days. Overall, the effect lasts 2 to 8 months, depending on the treatment area and individual response.

Precautions

• For use by licensed medical professionals only
• Contraindicated in patients with neuromuscular junction disorders, such as myasthenia gravis
• Contraindicated during pregnancy or breastfeeding
• Avoid in patients with known hypersensitivity to any component
• Use caution with concurrent muscle relaxants or aminoglycoside antibiotics
• Reported systemic reactions include nasopharyngitis and headache in a small percentage of patients; avoid injecting near sensitive structures to reduce the risk of muscle weakness or ptosis

Storage & Handling

• Store unopened vials refrigerated at 2–8°C
• Do not freeze
• Protect from light
• Use within 24 hours after reconstitution

Botulinum toxin type A is a prescription medical product for use by licensed healthcare professionals only. Liztox is MFDS-approved in South Korea but is not FDA-approved for the US market; this product is not available for purchase or shipment to US addresses.

Frequently Asked Questions

What is Liztox 200UI?
Liztox 200UI is a 99.8%-pure botulinum toxin type A product from Huons Biopharma, offering double the standard unit count for larger treatment sessions or therapeutic applications.

Who is the 200UI vial best suited for?
Practitioners treating larger areas, multiple facial zones, or therapeutic applications like pediatric spasticity often prefer it, since it reduces the need for multiple vials.

Is Liztox 200UI the same as Hutox?
Yes. Specifically, Huons Biopharma markets the same formulation as Liztox within Korea and as Hutox in export markets, with a European launch also planned under the Hutox name.

How is Liztox 200UI different from the 100UI version?
Both share the same formulation and manufacturer. However, the 200UI vial simply contains double the toxin units, reducing the need for multiple vials in larger sessions.

---

Buy Liztox 200UI online from Korea Filler Experts, a trusted wholesale supplier of premium aesthetic injectables. We ship worldwide, excluding the United States.